| Title: |
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial |
| Authors: |
Buteau, James P; Martin, Andrew J; Emmett, Louise; Iravani, Amir; Sandhu, Shahneen; Joshua, Anthony M; Francis, Roslyn J; Zhang, Alison Y; Scott, Andrew M; Lee, Sze-Ting; Azad, Arun A; McJannett, Margaret M; Stockler, Martin R; Williams, Scott G; Davis, Ian D; Hofman, Michael S; Akhurst, Tim; Alipour, Ramin; Banks, Patricia; Beaulieu, Alexis; Chua, Wei; Dhiantravan, Nattakorn; Ford, Kate; Gedye, Craig; Goh, Jeffrey C; Guminski, Alex; Hamid, Anis; Haskali, Mohammad B; Hicks, Rodney J; Hsiao, Edward; Kirkwood, Ian D; Kong, Grace; Kwan, Edmond M; Langford, Ailsa; Lawrence, Nicola; Lewin, Jeremy; Lin, Peter; McDonald, William; Moodie, Kate |
| Source: |
The Lancet Oncology ; volume 23, issue 11, page 1389-1397 ; ISSN 1470-2045 |
| Publisher Information: |
Elsevier BV |
| Publication Year: |
2022 |
| Collection: |
ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1016/s1470-2045(22)00605-2 |
| Availability: |
http://dx.doi.org/10.1016/s1470-2045(22)00605-2; https://api.elsevier.com/content/article/PII:S1470204522006052?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:S1470204522006052?httpAccept=text/plain |
| Rights: |
https://www.elsevier.com/tdm/userlicense/1.0/ ; http://www.elsevier.com/open-access/userlicense/1.0/ ; https://doi.org/10.15223/policy-017 ; https://doi.org/10.15223/policy-037 ; https://doi.org/10.15223/policy-012 ; https://doi.org/10.15223/policy-029 ; https://doi.org/10.15223/policy-004 |
| Accession Number: |
edsbas.EBEA803 |
| Database: |
BASE |